MYNZ Stock Risk & Deep Value Analysis
MYNZ
Healthcare • Diagnostics & Research
DVR Score
out of 10
What You Need to Know About MYNZ Stock
We analyzed MYNZ using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran MYNZ through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
MYNZ Risk Analysis & Red Flags
What Could Go Wrong
The planned 95.6% dilution of existing shareholders effectively extinguishes their equity stake, and the new post-quantum cybersecurity venture is entirely unproven, lacking established products, leadership, or funding beyond the current dilutive financing. If this new venture fails to secure significant funding or demonstrate viability within the next 12-18 months, the company faces liquidation or a complete loss for remaining shareholders.
Risk Matrix
Overall
Aggressive
Financial
High
Market
High
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Extreme 95.6% dilution of existing shareholders via preferred shares
- ⚠
Nasdaq delisting risk due to sub-$1.00 bid price
- ⚠
Auditors' 'going concern' doubt due to $16.2M net loss and $889k cash (Dec 31, 2025)
- ⚠
Complete business model pivot to an unproven post-quantum cybersecurity venture
- ⚠
Critical liquidity: Current ratio 0.52 and $1.9M working capital deficit
Upcoming Risk Events
- 📅
Nasdaq delisting (deadline September 16, 2026)
- 📅
Failure to secure sufficient funding for Quantum Cyber
- 📅
Failure of Quantum Cyber to develop viable products or secure market traction
- 📅
Further catastrophic dilution for existing shareholders
When to Reconsider
- 🚪
Confirmation of Nasdaq delisting
- 🚪
Any further announcement of significant shareholder dilution beyond the Lazar deal
- 🚪
Failure to articulate a clear strategy, leadership, or initial product roadmap for Quantum Cyber within 6 months
- 🚪
Decline in cash below critical operating levels without immediate, secured financing
Unlock MYNZ Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does MYNZ (MYNZ) Do?
Sector
Healthcare
Industry
Diagnostics & Research
Employees
19
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.
Visit MYNZ WebsiteInvestment Thesis
The investment thesis for MYNZ has been fundamentally reset to an ultra-speculative bet on the nascent and entirely unproven 'Quantum Cyber' post-quantum cybersecurity venture. This comes at the cost of a near-total wipeout of existing shareholder value through extreme dilution. Success would require the new entity to rapidly develop leading technology, secure substantial non-dilutive funding, and establish market leadership in a highly competitive and complex emerging industry, overcoming severe financial and execution challenges.
Is MYNZ Stock Undervalued?
Unlock the full AI analysis for MYNZ
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
MYNZ Price Targets & Strategy
12-Month Target
$0.05
Bull Case
$0.25
Bear Case
$0.01
Valuation Basis
Reflects a severe haircut due to 95.6% dilution, going concern, and unproven business pivot, assuming minimal residual asset value from the former business.
Entry Strategy
Avoid at current levels. Extreme risk given the imminent 95.6% dilution and uncertain new business. Any speculative entry would require significant price discovery post-dilution and concrete evidence of a viable business model for Quantum Cyber.
Exit Strategy
Immediate exit for risk-averse investors. For speculators, consider exiting if no clear strategy or significant non-dilutive funding for Quantum Cyber is announced within 6 months, or upon actual delisting.
Portfolio Allocation
0% for all risk tolerances. This is effectively a lottery ticket, not an investment.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Does MYNZ Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Eroding (any previous speculative moat related to ColoAlert is now gone)
Non-existent, as the company is starting from scratch in a new, highly competitive field without identifiable unique assets or advantages.
Moat Erosion Risks
- •Intense competition from established cybersecurity firms and emerging quantum startups
- •Lack of proprietary technology or IP in the new field
- •Significant capital requirements to build out a competitive cybersecurity offering
MYNZ Competitive Moat Analysis
Sign up to see competitive advantages
MYNZ Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bearish (likely due to extreme dilution and pivot to unproven venture)
Institutional Sentiment
Negative (analyst 'Hold' rating is effectively negative given existential risks and dilution; no institutional ownership data implies low interest)
Insider Activity (Form 4)
David Lazar acquired $6M in preferred shares ($3M at $1.00/share on Feb 13, 2026; $3M prepaid at $1.50/share in March 2026), structured to dilute existing shareholders by ~95.6% post-approval. This is a financing event, not a traditional insider buy indicating confidence in existing equity.
Options Flow
Normal options activity
Earnings Intelligence
Next Earnings
No data on expected date
Surprise Probability
Low (given lack of clear ongoing business and pivot)
Historical Earnings Pattern
N/A - Company undergoing fundamental business transformation.
Key Metrics to Watch
Competitive Position
Top Competitor
N/A (no defined product or market for 'Quantum Cyber' yet to identify a direct peer)
Market Share Trend
Losing (colorectal cancer screening business); N/A (post-quantum cybersecurity, as no presence yet)
Valuation vs Peers
N/A - Impossible to compare given the pivot to an unproven business with no current revenue or assets in the new sector. Current P/S of 9.67 (using $890k sales) is high for a company in such distress.
Competitive Advantages
- •None identified for the new cybersecurity venture
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive MYNZ Stock Higher?
Near-Term (0-6 months)
- •Nasdaq compliance decision by September 16, 2026
- •Initial strategic outline or leadership appointments for 'Quantum Cyber' (unspecified timeline)
Medium-Term (6-18 months)
- •First product development or partnership announcements for Quantum Cyber (highly speculative)
- •New, non-dilutive financing for the cybersecurity venture (unspecified timeline)
Long-Term (18+ months)
- •Establishment of market share and revenue streams in post-quantum cybersecurity
- •Broader adoption of quantum-resistant technologies in critical infrastructure
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for MYNZ?
- ✓
Explicit and detailed announcements of Quantum Cyber's product roadmap and technology stack
- ✓
Major strategic partnerships or customer wins for the new cybersecurity business
- ✓
Resolution of Nasdaq delisting issue and a clear path to long-term exchange compliance
- ✓
Significant, non-dilutive capital raises that validate the new business direction
Bull Case Analysis
See what could go right with Premium
Competing with MYNZ
See how MYNZ compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
MYNZ MYNZ | — | 0.5 | — | — | 0.0% | 0.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for MYNZ (MYNZ)?
As of April 4, 2026, MYNZ has a DVR Score of 0.5 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What ticker symbol does MYNZ use?
MYNZ is the ticker symbol for MYNZ. The company trades on the NCM.
What is the risk level for MYNZ stock?
Our analysis rates MYNZ's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is MYNZ's revenue growing?
MYNZ has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is MYNZ stock profitable?
MYNZ has a profit margin of 0.0%. The company is currently unprofitable.
How often is the MYNZ DVR analysis updated?
Our AI-powered analysis of MYNZ is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 4, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for MYNZ (MYNZ) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.